Full archive
Pharmacogenomics
Week of 14 July 2026
6 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►CYP2C9/VKORC1 — pharmacist-led warfarin management with genotyping improves time in therapeutic range in ventricular assist device patients.
- ►A pharmacogenomic panel guides antihypertensive prescribing and improves blood pressure control and adherence (RCT, 900 patients).
- ►CYP2D6 — phenotype (adjusted for phenoconversion) predicts atomoxetine discontinuation reason in children and adolescents.
- ►UGT1A1 — an editorial deems pre-irinotecan genotyping ready for routine care.
Category:
Filters··Min. score
6 articles of 6
Sort
Diabetes
PubMed★ Top pick
Optimizing Time in Therapeutic Range in Patients With HeartMate 3: Pharmacist-Led Anticoagulation Using Pharmacogenetics of Warfarin.
Warfarin anticoagulation (HeartMate 3 left ventricular assist device)
0
DiabetesCPIC Level APreemptive genotyping
Ann Pharmacother 2026· JulRead
Diabetes
PubMedPreliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension.
Arterial hypertension (antihypertensive therapy)
0
DiabetesPreemptive genotypingAdverse reaction
Med Sci Monit 2026· JulRead
CYP2D6
PubMedAssociation of Atomoxetine Discontinuation Patterns with CYP2D6 Phenotype in Children and Adolescents with Attention Deficit Hyperactivity Disorder.
Attention-deficit/hyperactivity disorder (atomoxetine)
0
PhenoconversionAdverse reaction
J Child Adolesc Psychopharmacol 2026· JulRead
CYP2C19
PubMedMachine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.
Dual antiplatelet therapy after percutaneous coronary intervention
0
CardiologyCPIC Level ARecurrent variant
Clin Transl Sci 2026· JulRead
UGT1A1
JournalUGT1A1 and irinotecan: Ready for routine pharmacogenetic care
Irinotecan toxicity (chemotherapy)
0
Preemptive genotypingAdverse reaction
Br J Clin Pharmacol 2026· JulRead
Psychiatry
PubMedIndividualized pharmacogenomics for depressive episodes: A narrative review.
Depressive episodes (major depression and bipolar disorder)
0
PsychiatryCPIC Level ANew recommendation
J Affect Disord 2026· JulRead
References and sources
- Warfarin anticoagulation (HeartMate 3 left ventricular assist device). Ann Pharmacother 2026. PMID 42426980. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42426980/
- CYP2D6 — Attention-deficit/hyperactivity disorder (atomoxetine). J Child Adolesc Psychopharmacol 2026. PMID 42433076. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42433076/
- CYP2C19 — Dual antiplatelet therapy after percutaneous coronary intervention. Clin Transl Sci 2026. PMID 42427167. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42427167/
- Arterial hypertension (antihypertensive therapy). Med Sci Monit 2026. PMID 42421289. Score 8/10. https://pubmed.ncbi.nlm.nih.gov/42421289/
- UGT1A1 — Irinotecan toxicity (chemotherapy). Br J Clin Pharmacol 2026. doi:10.1002/bcp.70692. Score 5/10. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70692?af=R
- Depressive episodes (major depression and bipolar disorder). J Affect Disord 2026. PMID 42442668. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42442668/
